Holen Sie sich die Stockscreener-App
34.69
1.36%
-0.48
Handel nachbörslich:
34.65
-0.04
-0.12%
Schlusskurs vom Vortag:
$35.17
Offen:
$34.21
24-Stunden-Volumen:
734.83K
Relative Volume:
1.03
Marktkapitalisierung:
$14.72B
Einnahmen:
$5.81B
Nettoeinkommen (Verlust:
$412.00M
KGV:
36.90
EPS:
0.94
Netto-Cashflow:
-
1W Leistung:
+1.61%
1M Leistung:
+2.33%
6M Leistung:
-2.28%
1J Leistung:
+37.39%
1-Tages-Spanne:
$34.20
$34.72
1-Wochen-Bereich:
$33.75
$35.35
52-Wochen-Spanne:
$23.91
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Firmenname
Smith Nephew Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare SNN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
34.69 | 14.93B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
110.83 | 189.68B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
358.29 | 138.60B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
102.90 | 131.98B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.27 | 115.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.71 | 45.32B | 5.88B | 1.34B | 799.60M | 2.3489 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-14 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-03-12 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-06 | Herabstufung | Berenberg | Buy → Hold |
| 2024-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-07-24 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-05 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-28 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-11-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-10-31 | Hochstufung | HSBC Securities | Hold → Buy |
| 2023-10-13 | Eingeleitet | Stifel | Hold |
| 2023-08-08 | Hochstufung | UBS | Sell → Neutral |
| 2023-04-27 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | Eingeleitet | Citigroup | Buy |
| 2022-11-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-07-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-04 | Hochstufung | Redburn | Sell → Neutral |
| 2021-06-09 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | Eingeleitet | Barclays | Overweight |
| 2020-07-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-21 | Eingeleitet | Citigroup | Buy |
| 2019-11-12 | Eingeleitet | Bernstein | Outperform |
| 2019-07-23 | Hochstufung | Berenberg | Hold → Buy |
| 2019-02-08 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-12-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-27 | Herabstufung | Goldman | Buy → Neutral |
| 2017-01-19 | Eingeleitet | HSBC Securities | Hold |
| 2016-12-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | Herabstufung | Berenberg | Buy → Hold |
| 2016-02-26 | Eingeleitet | Cantor Fitzgerald | Hold |
Alle ansehen
Smith Nephew Plc Adr Aktie (SNN) Neueste Nachrichten
Orthopedic Implants Market Size to Reach USD 33.20 Billion by 2033, Driven by Rising Musculoskeletal Disorders and Surgical Innovation – SNS Insider - GlobeNewswire Inc.
Jim Cramer on Smith & Nephew: "This Group, I Do Not Like" - Finviz
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair - Finviz
The Truth About Smith & Nephew plc: Why This ‘Boring’ Med-Tech Stock Might Be Your Sneaky Power - AD HOC NEWS
Smith & Nephew ADR trying to close in on key technical benchmark - MSN
The Truth About Smith & Nephew plc (ADR): Wall Street Sleeper Stock or Total Snooze? - AD HOC NEWS
Smith & Nephew plc (ADR): Quiet Charts, Cautious Optimism – Is SNN a Sleeper in Medtech? - AD HOC NEWS
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next - ts2.tech
Smith and Nephew (LON:SN) positioned across FTSE 100 Today healthcare landscape - Kalkine Media
FTSE 100 today: Pound lower; Magnum debuts, Smith & Nephew sets new goals - Investing.com
Smith & Nephew Unveils RISE Blueprint for a Stronger Future - Kalkine Media
Smith+Nephew sets ambitious growth targets through 2028 - Investing.com
Smith & Nephew (SNN) Stock Forecast 2026: Q3 2025 Results, $500m Buyback and New Board Signals - TechStock²
Smith & Nephew PLC (NYSE:SNN): A Value Investment in Medical Devices - Chartmill
[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer) | SNN SEC FilingForm 6-K - Stock Titan
Smith & Nephew PlcDirector/PDMR Shareholding - Research Tree
REGSmith & Nephew PlcDirector/PDMR Shareholding - TradingView
Smith & Nephew stock initiated with Buy rating at Kepler Cheuvreux - Investing.com
Shell Stock Price Today (12 Nov 2025): SHEL ADR edges lower as oil slides; London closes at 2,909p amid fresh buyback and Volta Media sale - ts2.tech
Smith+Nephew shares tumble as Q3 sales miss expectations - Investing.com
Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $36.75 - Defense World
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Predictions - sharewise.com
UFC® and Smith+Nephew announce multi-year extension of partnership - The Globe and Mail
Smith & Nephew stock price target raised to GBP17 by RBC on growth outlook - Investing.com Australia
Smith & Nephew schedules third quarter trading report release for November 6 - Investing.com
BlackRock Adjusts Voting Rights in Smith & Nephew - The Globe and Mail
Smith & Nephew stock rating downgraded by Bernstein as valuation recovers - Investing.com
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant - Sahm
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - Sahm
Smith & Nephew’s ratings affirmed by Moody’s with positive outlook - Investing.com
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - The Globe and Mail
Park Avenue Securities LLC Acquires 583 Shares of Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew CFO John Rogers relocates to US, receives revised compensation - Investing.com
Citi Keeps Their Hold Rating on Koninklijke Philips N.V. (0LNG) - The Globe and Mail
Smith & Nephew (LON:SN) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Finanzdaten der Smith Nephew Plc Adr-Aktie (SNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
2.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):